Research programme: T cell therapy - Chimeric Therapeutics

Drug Profile

Research programme: T cell therapy - Chimeric Therapeutics

Alternative Names: CAR-T cell therapy - Chimeric Therapeutics

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator Chimeric Therapeutics
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action C-type lectin modulators; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Jan 2016 Preclinical trials in Solid tumours in United Kingdom (Parenteral) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top